Additionally, in the MSKCC pan-cancer cohort of 10,336 patients, the overwhelming majority of whom have not received ICI-based immunotherapy, there was no significant association between mutation to any of these genes and time-to-endpoint survival outcomes, with the exception of VHL which was associated with improved overall survival (Table S4). This evidence concerns the gene VHL and cancer.